Intravenous haloperidol for the treatment of intractable vomiting,cyclical vomiting,and gastroparesis  

作　　者：Brad E.Schwartz Karen Keller Baker Andrew J.Bleinberger Amina Lleshi Raul Cruz-Cano 

机构地区：[1]Department of Emergency Medicine,University of Maryland Capital Region Health,UM Prince George’s Hospital Center,Cheverly 20785,USA [2]Ross University School of Medicine Bridgetown,Bridgetown 11093,Barbados [3]Department of Epidemiology and Biostatistics,School of Public Health of the University of Maryland,Baltimore 21201,USA

出　　处：《World Journal of Emergency Medicine》2021年第3期228-231,共4页世界急诊医学杂志（英文）

摘　　要：Dear editor,The incidence of emergency department(ED)visits from gastroparesis and cannabinoid hyperemesis syndrome has increased by two folds over the past decade.[1-3]Roldan et al[4]reported that patients with these conditions often have prolonged ED stays and are likely to be hospitalized because of the danger of dehydration and challenges inherent in relieving symptoms.Opioid analgesia is a particularly troublesome treatment modality;these conditions are often chronic with frequent recurrences,and repeated opiate therapy can cause opioid dependency and narcotic bowel syndrome.[5]Haloperidol(HP)and droperidol,members of the butyrophenone class,have potent antidopaminergic activity in the chemoreceptor trigger zone.[6,7]Intramuscular administration of HP is being used increasingly in the ED to treat nausea,vomiting secondary to gastroparesis,[6]intractable vomiting,[8]and cyclical vomiting.

关 键 词：VOMITING gastro TREATMENT 

分 类 号：R969.4[医药卫生—药理学]